Abstracts tagged "risk factors"

Abstract Number: 1063 • ACR Convergence 2023
Impact of Aging on Rheumatic Immune-related Adverse Events Secondary to Immune Checkpoint Inhibitors: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Jenny Li¹, Marie Hudson², Carrie Ye³, Janet Roberts⁴, Aurore Fifi-Mah⁵, May Choi⁵, Sabrina Hoa⁶, Thomas Appleton⁷, Janet Pope⁷, Nancy Maltez⁸, Lourdes Gonzalez Arreola⁹, Anthony Obrzut⁹ and Shahin Jamal¹⁰, ¹University of British Columbia, Vancouver, BC, Canada, ²McGill University, Montréal, QC, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶University of Montreal, Brossard, QC, Canada, ⁷University of Western Ontario, London, ON, Canada, ⁸The Ottawa Hospital, Ottawa, ON, Canada, ⁹Arthritis Research Canada, Vancouver, BC, Canada, ¹⁰Vancouver Coastal Health, Vancouver, BC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy. Their use is complicated by development of immune-related adverse effects (irAEs), including rheumatic irAEs (Rh-irAE). Aging…
Abstract Number: 1675 • ACR Convergence 2023
Survival in Patients with Rheumatoid Arthritis and Early Breast Cancer Treated with Tumor Necrosis Factor Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei², Chi-Fang Wu², Hui Zhao², Suja Rajan³, Heather Lin² and Sharon Giordano², ¹MD Anderson Cancer Center, Houston, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas School of Public Health, Houston, TX
Background/Purpose: There have been concerns about the use of tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) and concomitant cancer. Few studies…
Abstract Number: 2268 • ACR Convergence 2023
Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Poor COVID-19 outcomes in patients with systemic lupus erythematosus (SLE) has been found to be associated with glucocorticoid dose, male sex, older age, mycophenolate,…
Abstract Number: 2600 • ACR Convergence 2023
Clonal Hematopoiesis Is Associated with Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is an age-related vasculitis of large and medium vessels. Prior population studies have identified an association between GCA and hematologic…
Abstract Number: 0396 • ACR Convergence 2023
Hydroxychloroquine Is Associated with a Decreased Risk of Non-alcoholic Fatty Liver Disease in Patients with Rheumatoid Arthritis: A Population-based, Cohort Study
Hsin-Hua Chen¹ and DER-YUAN CHEN², ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Center of Rheumatology, China Medical University Hospital, Taichung, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease characterized by chronic destructive arthritis and extra-articular involvement. Prior studies showed patients with RA had…
Abstract Number: 1074 • ACR Convergence 2023
Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Laura Cappelli¹, omer Kamal², Michelle Jones³, Clifton Bingham⁴ and Ami Shah⁵, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²St. Agnes Hospital, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD
Background/Purpose: Immune checkpoint inhibitors (ICI) can cause inflammatory arthritis (IA) of varying severity. Many patients with ICI-IA require immunosuppression beyond corticosteroids, but there is no…
Abstract Number: 1685 • ACR Convergence 2023
SLE Disease Activity Is a More Important Risk Factor Than Immunosuppression for Acquiring Human Papillomavirus (HPV) Infection in Systemic Lupus Erythematosus Patients
Zehra Kazmi¹, Carlos Lorenzo² and Agustin Escalante³, ¹University of Texas Health Science Center at San Antonio, San Antonio, TX, ²UT Heath San Antonio, Shavano Park, TX, ³UT Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: SLE patients have increased rates of HPV infection and cervical cancer. Although some factors are recognized for HPV infection in SLE, the relationship with…
Abstract Number: 2289 • ACR Convergence 2023
Short and Long Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease
Fadi Kharouf¹, Juan Pablo Diaz Martinez², Dafna Gladman³ and Zahi Touma⁴, ¹University Health Network and University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
b>Background/Purpose: Patients with pure membranous lupus nephritis (LN) are known to have a different disease course than those with proliferative disease. The aim of this…
Abstract Number: 0406 • ACR Convergence 2023
Obesity Is a Risk Factor for Poor Response to Treatment in Early Rheumatoid Arthritis – a NORD-STAR Spin-Off Study
Violetta Dubovyk¹, Gerdur Maria Grondal², Bjorn Gudbjornsson³, Espen A Haavardsholm⁴, Marte Schrumpf Heiberg⁴, Merete Hetland⁵, Kim Hørslev-Petersen⁶, Meliha Kapetanovic⁷, Alf Kastbom⁸, John Lampa⁹, Kristina Lend¹⁰, Dan Nordstrom¹¹, Michael Nurmohamed¹², Milad Rizk¹³, Annika Söderbergh¹⁴, Till Uhlig¹⁵, Mikkel Østergaard¹⁶, Ronald van Vollenhoven¹², Anna Rudin¹⁷ and Cristina Maglio¹⁸, ¹University of Gothenburg, Gothenburg, Sweden, ²Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ³Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁶University of Southern Denmark, Odense, Denmark, ⁷Lund University and Skåne University Hospital, Lund, Sweden, ⁸Linköping University, Linköping, Sweden, ⁹Stockholm County, Hãsselby, Sweden, ¹⁰Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹³Västmanlands Hospital Västerås, Västerås, Sweden, ¹⁴Örebro University Hospital, Örebro, Sweden, ¹⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ¹⁷Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ¹⁸Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Several therapeutic options are currently available to treat rheumatoid arthritis (RA); however, the response to treatment is highly variable, and not all patients achieve…
Abstract Number: 1078 • ACR Convergence 2023
Outcomes of COVID-19 Infection in Hospitalized Autoimmune Patients and Transplant Patients on Immunosuppression
Yashswee KC¹ and Rochella Ostrowski², ¹Loyola University, Oakpark, IL, ²Loyola University Medical Center, Maywood, IL
Background/Purpose: Coronavirus disease 2019 (COVID-19) can have varying outcomes. Patients with chronic conditions or immunosuppression experience more severe illness. Both organ transplant recipients and patients…
Abstract Number: 1700 • ACR Convergence 2023
Incidence and Risk Factors for New Onset of Interstitial Lung Disease in Systemic Sclerosis: A EUSTAR Analysis
liubov Petelytska¹, Arthiha Velauthapillai², Lorenzo Tofani³, Eric Hachulla⁴, Ulf Müller-Ladner⁵, Elise Siegert⁶, Yannick ALLANORE⁷, Gabriela Riemekasten⁸, Christina Bergmann⁹, Radim Becvar¹⁰, Kamal Solanki¹¹, Branimir Anic¹², Simona Rednic¹³, Bojana Stamenkovic¹⁴, Lisa Stamp¹⁵, Joerg Distler¹⁶, Madelon Vonk¹⁷, Jeska de Vries-Bouwstra¹⁸, Anna Maria Hoffmann-Vold¹⁹, marco Matucci Cerinic²⁰, Oliver Distler²¹ and Cosimo Bruni²¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, ⁴University of Lille, Lille, France, ⁵Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ⁶Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁷Université Paris Cité, Paris, France, ⁸University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ⁹Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ¹⁰Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic, ¹¹Department of Rheumatology, Te Whatu Ora Health New Zealand Waikato, Hamilton, New Zealand, ¹²Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Kišpatićeva 12, 10 000, Zagreb, Croatia, ¹³Prof Dr Simona Rednic, Cluj, Romania, ¹⁴Institut Niska Banja, Niska Banja, Serbia, ¹⁵University of Otago, Christchurch, New Zealand, ¹⁶Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ¹⁷Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁸Leiden University Medical Center, Leiden, Netherlands, ¹⁹Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ²⁰Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ²¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Although prevalence of interstitial lung disease (ILD) in systemic sclerosis (SSc) and associated risk factors are established, less is known about its incidence and…
Abstract Number: 2308 • ACR Convergence 2023
The Association Between Poverty and SLE Disease Burden: Experiences from a Saint Lucian Cohort
Amanda King¹, Catherine Brown², Cleopatra Altenor¹, Timothy Niewold³ and Ashira Blazer³, ¹Bay Medical Centre, Castries, Saint Lucia, ²The University of the West Indies, Bridgetown, Barbados, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Poverty increases non-communicable disease risk, however its influence on systemic lupus erythematosus (SLE) burden is poorly understood. Non-White racial/ethnic groups, particularly of African origin,…
Abstract Number: 0416 • ACR Convergence 2023
Association Between Sleep Disorders and Rheumatoid Arthritis: A Population-based Cohort Study
Rakesh Kumar¹, Edward Lovering¹, Chanakya Kodishala², Sara Achenbach³, Diego Carvalho¹, Cynthia Crowson¹, John Davis¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester Minnesota, Rochester, MN, ³Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Some sleep disorders (SD) are more prevalent in patients with chronic inflammatory diseases, such as Rheumatoid Arthritis (RA). However, most of the research has…
Abstract Number: 1080 • ACR Convergence 2023
Prevalence and Incidence of Paradoxical Side-effects of TNF-α Inhibitors: A Cross-sectional Study
Antoine Minier¹, Gilles Boire¹, Sophie ROUX¹, Nathalie Carrier² and Hugues Allard-Chamard¹, ¹Université de Sherbrooke, Sherbrooke, QC, Canada, ²CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada
Background/Purpose: Tumor necrosis factor alpha inhibitors (TNFi) are used to treat a variety of inflammatory conditions ranging from rheumatoid arthritis to sarcoidosis. Paradoxical side-effects (PSE)…
Abstract Number: 1746 • ACR Convergence 2023
Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies
Tineke van Wesemael¹, Anna Svärd², Annemarie Dorjee¹, Thomas Huizinga¹, René Toes¹ and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Centre for Clinical Research Dalarna, Uppsala, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies to anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). Smoking is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].